跳至主要内容
临床试验/NCT05814887
NCT05814887已完成不适用

Reduction of Mechanical IV Complication Using a New Medical Device

Uppsala University Hospital2 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2023年5月4日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
200
试验地点
2
主要终点
The rate of mechanical complications of an IV therapy session using a new medical device (ReLink) compared to using current 'state of the art'.

研究概览

简要总结

Peripheral intravenous catheters are necessary for in-hospital medical treatment. Malfunction due to occlusion or dislodgement is common, and increases the burden on health care.

The aim of this study is to determine if the use of a new medical device has an impact on mechanical complications rate when peripheral intravenous (IV) catheter is used. The study will also investigate the safety, opinions of healthcare personnel and health economic effects of this new device,

详细描述

It is estimated that around 1.5 billion peripheral intravenous catheters (PIVC) are sold every year globally, and placing them is one of the most common invasive procedures in hospitalised patients, with up to 90% receiving one, yet there is a failure rate of up to 69%. Some of the most common causes of failure are considered to be phlebitis, subcutaneous infiltration, occlusion and dislodgement. These failure rates vary widely, where published data suggests rates of 8-44% for phlebitis, 5-21% for infiltration, 7.6-16% for occlusion and 5-10% for dislodgement. Phlebitis, commonly defined as an inflammatory process in the wall of a vein, resulting in a blood clot formation; while infiltration is defined as the inadvertent leakage of a solution into the surrounding tissue; occlusion is defined as PIVC failure due to blockage where flushing and/or aspiration is not possible, and dislodgement the complete accidental/inadvertent removal of the PIVC before intended. Previous studies have suggested that mechanical irritation could be an important factor resulting in PIVC failure. In the case of phlebitis, mechanical movements against the endothelial wall could initiate a cascade of prothrombotic events resulting in the formation of a blood clot, something that has been demonstrated in a simulated environment.

Therefore, there is a need to investigate potential new methods for prevention of these mechanical complications, and one way could be in the reduction of mechanical forces acting on the vessels. The aim of this study is to investigate the safety and effectiveness of a new medical device in reducing the number of mechanical complications during IV therapy.

The investigators have divided the research questions into a primary endpoint and secondary endpoints.

  1. Primary endpoint:

The rate of mechanical complications of an IV therapy session using a new medical device (ReLink) compared to using current 'state of the art'. 2. Secondary endpoint:

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • The patient has or will get a PIVC expected to be used for continuous or intermittent IV infusion therapy. Continuous IV infusion is defined as an infusion ≥ 2h and intermittent as an infusion lasting 15min to < 2h.
  • ≥18 years of age
  • Speaks and understands Swedish

排除标准

  • The PIVC is expected to be used for sampling only
  • Pregnancy
  • Unable to obtain informed consent or without an available Next-of-kin to provide surrogate informed consent
  • Patients under palliative care
  • Bolus IV infusion, defined as an infusion time of <15 min
  • Phlebitis, infiltration or occlusion associated with PIVC that is already in place at the time of inclusion

结局指标

主要结局

The rate of mechanical complications of an IV therapy session using a new medical device (ReLink) compared to using current 'state of the art'.

时间窗: Up to one week from randomization

Mechanical complications is defined as phlebitis, subcutaneous infiltration, occlusion or dislodgement

次要结局

  • The economic cost of these disruptions to the hospital or healthcare facility in terms of man-hours, and resources(Through study completion, an average of 1 year)
  • Frequency and severity of any adverse events(Up to one week from randomization)
  • Healthcare workers opinion of the new medical device(Within one week of removal of the device)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Peter Frykholm

Associate Professor

Uppsala University Hospital

研究点 (2)

Loading locations...

相似试验

Reduction of Mechanical IV Complication Using a New... | 临床试验